Outlook Therapeutics Inc (NASDAQ:OTLK)’s traded shares stood at 2.34 million during the last session, with the company’s beta value hitting 0.58. At the close of trading, the stock’s price was $2.19, to imply a decrease of -4.78% or -$0.11 in intraday trading. The OTLK share’s 52-week high remains $12.85, putting it -486.76% down since that peak but still an impressive 60.27% since price per share fell to its 52-week low of $0.87. The company has a valuation of $54.54M, with an average of 1.0 million shares in intraday trading volume over the past 10 days and average of 1.93 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Outlook Therapeutics Inc (OTLK), translating to a mean rating of 1.40. Of 5 analyst(s) looking at the stock, 0 analyst(s) give OTLK a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.96.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
After registering a -4.78% downside in the last session, Outlook Therapeutics Inc (OTLK) has traded red over the past five days. The 5-day price performance for the stock is 0.46%, and 47.97% over 30 days. With these gigs, the year-to-date price performance is 15.87%. Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) saw shorts transact 4.13 million shares and set a 1.26 days time to cover.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Looking at statistics comparing Outlook Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Outlook Therapeutics Inc (OTLK) shares are -75.53% down over the last 6 months, with its year-to-date growth rate higher than industry average at 41.60% against 16.70%.
Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 702.6k.
OTLK Dividends
Outlook Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Outlook Therapeutics Inc insiders hold 35.58% of total outstanding shares, with institutional holders owning 35.63% of the shares at 55.31% float percentage. In total, 35.63% institutions holds shares in the company, led by ROSALIND ADVISORS, INC.. As of 2024-06-30, the company held over 0.45 million shares (or 3.1534% of shares), all amounting to roughly $3.32 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Outlook Therapeutics Inc (OTLK) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 442.51 shares. This is just over 1.78% of the total shares, with a market valuation of $0.97 million. Data from the same date shows that the other fund manager holds a little less at 369.41, or 1.48% of the shares, all valued at about 0.81 million.
